• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Entrada Therapeutics Inc.

    2/27/25 7:16:35 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRDA alert in real time by email
    S-8 1 tm257649d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-             

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    ENTRADA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware 81-3983399
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
       
    One Design Center Place
    Suite 17-500

    Boston, MA
    02210
    (Address of Principal Executive Offices) (Zip Code)

     

    Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan

    Entrada Therapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Dipal Doshi

    Chief Executive Officer

    Entrada Therapeutics, Inc.

    One Design Center Place

    Suite 17-500

    Boston, MA 02210

    (Name and address of agent for service)

     

    (857) 520-9158

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Kingsley L. Taft

    Sarah Ashfaq

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer x
           
    Non-accelerated filer ¨   Smaller reporting company x
           
          Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is filed for the purposes of registering (i) an additional 1,503,048 shares of common stock, par value $0.0001 per share (the “common stock”), of Entrada Therapeutics, Inc. (the “Registrant”) that may be issued pursuant to the Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the “2021 Plan”) and (ii) an additional 375,762 shares of common stock that may be issued pursuant to the Entrada Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The number of shares of common stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) such number of shares of common stock as determined by the Administrator (as defined in the 2021 Plan). Accordingly, on January 1, 2025, the number of shares of common stock reserved and available for issuance under the 2021 Plan increased by 1,503,048. This Registration Statement registers these additional 1,503,048 shares of common stock. The additional shares are of the same class as other securities relating to the 2021 Plan for which the Registrant’s registration statements filed on Form S-8 (File No. 333-260563, File No. 333-263556, File No. 333-270286 and File No. 277868) filed with the Securities and Exchange Commission (the “SEC”) on October 28, 2021, March 15, 2022, March 6, 2023 and March 13, 2024, respectively, are effective. The number of shares of common stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of: (i) 557,524 shares of common stock, (ii) one percent (1%) of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (iii) such number of shares of common stock as determined by the Administrator (as defined in the 2021 ESPP). Accordingly, on January 1, 2025, the number of shares of common stock reserved and available for issuance under the 2021 ESPP increased by 375,762. This Registration Statement registers these additional 375,762 shares of common stock. The additional shares are of the same class as other securities relating to the 2021 ESPP for which the Registrant’s registration statements filed on Form S-8 (File No. 333-260563, File No. 333-263556, File No. 333-270286 and File No. 277868) filed with the SEC on October 28, 2021, March 15, 2022, March 6, 2023 and March 13, 2024, respectively, respectively, are effective. The information contained in the Registrant’s registration statements on Form S-8 (File No. 333-260563, File No. 333-263556, File No. 333-270286 and File No. 277868) is hereby incorporated by reference pursuant to General Instruction E, except for “Item 8. Exhibits.”

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    See the Exhibit Index for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
    4.1   Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40969) filed by the Registrant on November 2, 2021).
         
    4.2   Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-40969) filed by the Registrant on June 13, 2024).
       
    4.3   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40969) filed by the Registrant on November 2, 2021).
       
    4.4   Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, dated as of March 29, 2021 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-260160), filed by the Registrant on October 8, 2021).
         
    4.5   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Registrant on June 24, 2024).
       
    5.1*   Opinion of Goodwin Procter LLP.
       
    23.1*   Consent of Ernst & Young LLP, independent registered public accounting firm.
       
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (included on signature page).
       
    99.1   2016 Stock Incentive Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260160), filed by the Registrant on October 25, 2021).
       
    99.2   2021 Stock Option and Incentive Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40969), filed by the Registrant on February 27, 2025).
       
    99.3   2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260160), filed by the Registrant on October 25, 2021).
       
    107*   Filing Fee Table.

     

    *   Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 27th day of February, 2025.

     

      ENTRADA THERAPEUTICS, INC.
         
      By: /s/ Dipal Doshi
      Name: Dipal Doshi
      Title: Chief Executive Officer (Principal Executive Officer)

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Dipal Doshi and Kory Wentworth as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their capacities and on the date indicated below.

     

    Name   Title   Date
    /s/ Dipal Doshi   Chief Executive Officer and Director   February 27, 2025
    Dipal Doshi   (Principal Executive Officer)    
             
    /s/ Kory Wentworth   Chief Financial Officer   February 27, 2025
    Kory Wentworth   (Principal Financial and Accounting Officer)    
             
    /s/ Kush M. Parmar, M.D., Ph.D.   Chairman and Director   February 27, 2025
    Kush M. Parmar, M.D., Ph.D.        
             
    /s/ Gina Chapman   Director   February 27, 2025
    Gina Chapman        
             
    /s/ Peter S. Kim, Ph.D.   Director   February 27, 2025
    Peter S. Kim, Ph.D.        
             
    /s/ Mary Thistle   Director   February 27, 2025
    Mary Thistle        
             
    /s/ Bernhardt Zeiher, M.D.   Director   February 27, 2025
    Bernhardt Zeiher, M.D.        

     

     

     

    Get the next $TRDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRDA

    DatePrice TargetRatingAnalyst
    2/11/2026$20.00Buy
    Guggenheim
    1/28/2026$21.00Outperform
    Oppenheimer
    12/6/2024$29.00Buy
    ROTH MKM
    1/5/2024$22.00Outperform
    Oppenheimer
    4/3/2023$25.00Buy
    H.C. Wainwright
    11/24/2021Outperform
    Evercore ISI Group
    11/23/2021Outperform
    Cowen & Co.
    11/23/2021$29.00Neutral
    Goldman Sachs
    More analyst ratings

    $TRDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Wentworth Kory James sold $88,932 worth of shares (8,910 units at $9.98), decreasing direct ownership by 7% to 110,026 units (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:30:41 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:09:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parmar Kush sold $1,760,000 worth of shares (200,000 units at $8.80) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/18/25 4:36:30 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Entrada Therapeutics to Present at Upcoming Investor Conferences

    BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the

    2/4/26 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

    -- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 – -- Cash runway into Q3 2027 – -- Entrada to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) -- BOSTON, Jan. 08, 2026

    1/8/26 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage int

    12/17/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $261,846 worth of shares (28,867 units at $9.07) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/24/25 4:09:49 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Baker Bros. Advisors Lp bought $1,352,587 worth of shares (178,044 units at $7.60) (SEC Form 4)

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    11/12/25 5:34:18 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)

    4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    6/18/25 4:32:46 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

    Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $21.00

    1/28/26 7:58:46 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Entrada Therapeutics with a new price target

    ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00

    12/6/24 8:19:11 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    SEC Filings

    View All

    Entrada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

    1/8/26 7:25:52 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Entrada Therapeutics Inc.

    EFFECT - Entrada Therapeutics, Inc. (0001689375) (Filer)

    12/4/25 12:15:14 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Entrada Therapeutics Inc.

    SCHEDULE 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

    11/25/25 4:29:15 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Leadership Updates

    Live Leadership Updates

    View All

    Entrada Therapeutics Reports Second Quarter 2025 Financial Results

    -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to

    8/6/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

    BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

    6/3/25 7:00:00 AM ET
    $BIIB
    $TRDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

    āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

    9/17/24 8:30:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Entrada Therapeutics Inc.

    SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    11/14/24 1:22:40 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Entrada Therapeutics Inc.

    SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    6/26/24 4:54:17 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Entrada Therapeutics Inc. (Amendment)

    SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

    2/14/24 4:26:22 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care